Pankaj Desai

Pankaj Desai , PhD


Chair of Pharmaceutical Sciences Division

UC College of Pharmacy
Wherry Hall, Room 210
Phone 513-558-3870

Professional Summary

Pankaj B. Desai is currently Professor and Director, Drug Development Graduate Program, College of Pharmacy, University of Cincinnati, Cincinnati, OH. His research interests include pre-clinical and clinical studies on drug metabolism, transport and pharmacokinetics. The current focus of his laboratory is on the regulation of drug-metabolizing enzymes and its relevance to clinical pharmacology of anti-cancer and antiretroviral drugs. Dr. Desai directs a vigorous, extramurally-funded research program and has authored numerous peer-reviewed publications. His research has been funded by NIH, Komen Foundation, American Cancer society and various pharmaceutical companies. He has mentored over 20 MS/Ph.D. students and was the principal architect for the novel graduate curriculum in drug development program at UC College of Pharmacy. Dr. Desai is an active member of several organizations including American Association of Pharmaceutical Scientists, where he served as the chair of the Drug Metabolism Focus Group of AAPS from 2001-2003. He is currently a member of the Shulman Associates Institutional Review Board and of the Transitional Research and Drug Development (TRADD) Committee and Phase I /Early Clinical Pharmacology sub-committee of the Adults AIDS Clinical Trials Group. He also serves as a member of the Experimental Therapeutics Study Section for Department of Defense Breast Cancer Research Program. Dr. Desai has received numerous teaching and research excellence awards at both University of Louisiana and University of Cincinnati. These include the Researcher of the Year Award at ULM in 1994 and the President’s Excellence Award at UC in 2006.

Research and Practice Interests

Pharmacokinetics and pharmacodynamics of anticancer drugs, inter-individual and inter-species variation in drug metabolism, drug delivery systems

Research Support

Investigators:Desai, Pankaj 05-01-2005 -07-31-2007 National Institute of General Medical Sciences Drug Interactions with Anti-HIV Protease Inhibitors Role:PI $158,754.00 Closed Level:Federal

Investigators:Desai, Pankaj 08-01-2005 -07-31-2006 Bioavailability Systems, LLC Influence of Spiro-Ortho-Ester Compounds from Grapefruit Juice on CYP3A4 Activity and Expression Role:PI $31,250.00 Closed Level:Industry

Grant: #Aventis FY03-01-A0-S0-E0 Investigators:Desai, Pankaj 09-01-2002 -08-31-2004 Sanofi-Aventis (France) Fibrinogen - Coated Docetaxel Microemulsions: A Novel Approach for Drug Targeting Role:PI $111,849.00 Closed Level:Foreign Industry

Investigators:Desai, Pankaj 05-01-2004 -04-30-2006 Susan G. Komen Breast Cancer Foundation Induction of drug metabolism and transport genes and activation of human PregnaneX Receptor by Tamoxifen Role:PI $30,000.00 Closed Level:Private Non-Profit

Investigators:Desai, Pankaj 08-01-2003 -07-31-2004 Sanofi-Aventis (France) Assessment of Potentially Cincally Relevant Drug-Drug Interactions Role:PI $77,500.00 Closed Level:Foreign Industry

Investigators:Desai, Pankaj 12-01-2004 -11-30-2006 Bristol-Myers Squibb Co. Assessment of the Potential Induction of Hepatic and Intestinal Enzymes and Transporters by Efavirenz Role:PI $25,000.00 Closed Level:Industry

Grant: #RPR-11-01-A0-S0-E0 Investigators:Desai, Pankaj 01-01-2000 -12-31-2001 Rhone-Poulenc Rorer Pharmaceuticals CSF Pharmacokinetics of Taxotere in Combination with RMP-7 Role:PI $45,000.00 Closed Level:Industry

Grant: #PHOENIX-01-A0-S0-E0 Investigators:Desai, Pankaj 07-01-1999 -06-30-2001 Phoenix International Life Science, Inc. Innovative Pharmacokinetic-Pharmacodynamic Analyses Role:PI $9,910.00 Closed Level:Industry

Grant: #RPR-12-01-A0-S0-E0 Investigators:Desai, Pankaj 03-01-2000 -02-28-2001 Rhone-Poulenc Rorer Pharmaceuticals Induction of Hepatic Cytochrome P450 Enzyme(s) by Docetaxel Role:PI $50,000.00 Closed Level:Industry

Grant: #SUGEN-05-01-A0-S0-E0 Investigators:Desai, Pankaj 09-01-2000 -08-31-2002 Sugen, Inc. Pharmacokinetic Interaction Between Paclitaxel and SU5416 Role:PI $102,080.00 Closed Level:Industry

Grant: #ACS - Taxane-01-A0-S0-E0 Investigators:Desai, Pankaj 07-01-2001 -06-30-2002 American Cancer Society - Ohio Chapter Molecular Mechanisms for Increased CYP3A4 Expression by Taxane Anti-Cancer Agents Role:PI $19,800.00 Closed Level:Private Non-Profit

Grant: #2002-UC-41-02-A0-S0-E0 Investigators:Desai, Pankaj 07-01-2001 -06-30-2003 Eli Lilly and Company Influence of Ionizing Radiation on Brain Pharmacokinetics of Gemcitabine Role:PI $60,000.00 Closed Level:Industry

Grant: #BRISTOL-10-01-A0-S0-E0 Investigators:Desai, Pankaj 06-01-1997 -06-30-2000 Bristol-Myers Squibb Co. Evaluation of Pharmacokinetics and Pharmacodynamics of Radiation Sensitizing Doses of Taxol in Pancreatic Cancer Role:PI $25,000.00 Closed Level:Industry

Grant: #Komen BCTR0707983 PH Investigators:Chakraborty, Ranajit; Deka, Ranjan; Desai, Pankaj; Shaughnessy, Elizabeth 07-01-2007 -06-30-2010 Susan G. Komen Breast Cancer Foundation Clinical Assessment of Cytochrome P450 (CYP)3A4 Induction by Tamoxifen: Potential Impact of Hormonal and Genetic Factors Role:PI $297,968.00 Closed Level:Private Non-Profit

Grant: #SRS 006071 Investigators:Desai, Pankaj 01-20-2009 -10-31-2009 Abraxis BioScience, LLC Studies in Localized Delivery of Abraxane, a Novel Paclitaxel Dosage Form Role:PI $15,240.00 Closed Level:Industry

Grant: #SRS 006624 Investigators:Desai, Pankaj 10-01-2009 -09-30-2010 Johnson & Johnson The Effects of Darunavir Plus Ritonavir on the Pharmacokinetics and Pharmacodynamics of Rosuvastatin Role:PI $33,432.00 Closed Level:Industry

Grant: #SRS 006897 Investigators:Desai, Pankaj 06-01-2010 -05-31-2013 Eli Lilly and Company Pharmacokinetics of Paclitaxel and Gemcitabine in a Phase II Trial of Biweekly Gemcitabine, Paclitaxel and Bevacizumab as Frontline Therapy for Metastatic Breast Cancer Role:PI $9,000.00 Active Level:Industry

Grant: #1 R43 MH082461 Investigators:Desai, Pankaj 09-01-2010 -01-04-2011 National Institute of Mental Health Betahistine-Novel Therapeutic in Attention Deficit Hyperactivity Disorder Role:PI $18,000.00 Closed Level:Federal

Grant: #SRS 007158 Investigators:Desai, Pankaj 09-01-2010 -08-31-2012 Cincinnati Children's Hospital Medical Center Graduate Research (PhD) at the Division of Clinical Pharmacology at Cincinnati Children's Hospital Medical Center Role:PI $18,800.00 Closed Level:Private Non-Profit

Grant: #CRA - Desai Investigators:Desai, Pankaj 06-01-2012 -05-31-2013 Community Research CYP2D6 Genotyping in Phase I Studies Role:PI $62,846.00 Active Level:Industry

Grant: #CTA - Desai \ WS937635 Investigators:Desai, Pankaj 04-01-2012 -09-30-2013 Pfizer, Inc. Axitinib Pharmacokinetics and Pharmacodynamics in Patients with Glioblastoma Multiforme Role:PI $78,620.10 Active Level:Industry

Grant: #0000013121 / HDTRA1-12-C-0051 Investigators:Desai, Pankaj 10-01-2012 -09-30-2014 Defense Threat Reduction Agency Multi-pathogen Antiviral Medical Countermeasure Deploying FDA Approved Drug Role:PI $206,091.00 Active Level:Federal

Grant: #TECG20160468 Investigators:Desai, Pankaj 05-16-2016 -05-16-2017 Ohio Development Services Agency Novel Therapy for High Grade Gliomas: Repurposing Letrozole, an FDA Approved Drug, for an Orphan & Fast Track 505(b)(2) Application Role:PI $50,000.00 Active Level:State of Ohio

Grant: #17-65-BOGD Investigators:Ahmad, Syed; Bogdanov, Vladimir; Desai, Pankaj 07-01-2017 -06-30-2019 Pancreatic Cancer Network Disrupting Tissue Factor-beta1 integrin axis in pancreatic cancer Role:Collaborator $300,000.00 Active Level:Private Non-Profit

Grant: #HHSN272201700034I (Master Agreement) Investigators:Cushion, Melanie; Desai, Pankaj; Sallans, Larry 07-14-2017 -07-13-2024 National Institute of Allergy and Infectious Diseases PRE-CLINICAL MODELS OF INFECTIOUS DISEASES: Task Area A: Small Animal Models of Infectious Diseases Role:Collaborator $.00 Active Level:Federal

Grant: #139257 / W81XWH-17- 1-0666 Investigators:Desai, Pankaj; McCormack, Francis 09-30-2017 -09-29-2018 Department of the Army Medical Research Acquisition Activity Therapeutic Benefit of HSP90 Inhibition in Pulmonary Fibrosis Role:Collaborator $43,149.00 Awarded Level:Federal

Grant: #139257 / W81XWH-17-1-0666 (011239-yr1) Investigators:Desai, Pankaj; McCormack, Francis 10-01-2018 -09-30-2019 Department of the Army Medical Research Acquisition Activity Therapeutic Benefit of HSP90 Inhibition in Pulmonary Fibrosis Role:Collaborator $44,241.16 Active Level:Federal

Grant: #310252 / R01NS114074 Investigators:Desai, Pankaj 12-01-2019 -11-30-2021 National Institute of Neurological Disorders and Stroke Bystander gene deletions in cancer: mechanisms of therapeutic opportunities and challenges Role:PI $29,434.00 Awarded Level:Federal

Grant: #Laboratory Services Agreement Investigators:Desai, Pankaj 07-01-2020 -06-30-2021 Cincinnati Children's Hospital Medical Center Pharmacokinetic Analysis of Venetoclax Role:PI 20800.00 Active Level:Non Profit

Grant: #317613 / R01NS099162 Investigators:Desai, Pankaj 05-01-2022 -04-30-2027 Cincinnati Children's Hospital Medical Center Mechanisms of Biguanide Sensitivity in Glioma Role:PI 0.00 Hold Level:Non Profit

Grant: #R61NS128232 Investigators:Desai, Pankaj; Gudelsky, Gary; Phoenix, Timothy; Plas, David; Rodenberg, Cynthia; Sengupta, Soma; Wise-Draper, Trisha 08-01-2022 -07-31-2025 National Institute of Neurological Disorders and Stroke Translational Studies to facilitate Rational Therapeutic Combinations of Letrozole for the Treatment of Glioblastoma Role:PI 389244.00 Awarded Level:Federal

Investigators:Chaudhary, Rekha; Desai, Pankaj; Medvedovic, Mario; Plas, David; Rai, Shesh; Wise-Draper, Trisha; Zuccarello, Mario 11-30-2023 -11-30-2024 Dr. Ralph and Marian Falk Medical Research Trust Clinical and Correlative Translational Studies for Repurposing Letrozole as a Novel Therapeutic for Glioblastoma: Proof of Efficacy in Combination with Metronomic Temozolomide Role:PI 211322.00 Hold Level:Non Profit

Contact Information

Academic - UC College of Pharmacy
Wherry Hall, Room 210
Phone: 513-558-3870

Research - Desai's Lab
231 Albert Sabin Way
Cincinnati  Ohio, 45229
Phone: 513-558-0723